| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
Gastrointestinal Mucosa Pathology Laboratory, VA Medical Center and Baylor College of Medicine, Houston, Texas 77030, USA
Department of Medicine, VA Medical Center and Baylor College of Medicine
Dr El-Zimaity, Gastrointestinal Mucosa Pathology Laboratory, Rm 3A352, VA Medical Center (111-D), 2002 Holcombe Blvd, Houston, Texas 77030, USA hzimaity{at}bcm.tmc.edu Background—It has been suggested that the subtyping of intestinal metaplasia in the stomach is useful in stratifying patients with regard to risk of developing gastric cancer.
Aim—To determine whether subtyping intestinal metaplasia provided useful information regarding the natural history of intestinal metaplasia.
Methods—The study used large cup gastric biopsy specimens from predetermined locations (gastric mapping). Follow up biopsies were obtained at one, two, and/or nine years. Biopsies with intestinal metaplasia were stained with high iron diamine/Alcian blue (HID/AB) to determine whether they expressed neutral mucins, sialomucins, or sulphomucins.
Results—Seventy nine patients with intestinal metaplasia were studied and characterised with regard to the most advanced subtype of intestinal metaplasia. The most severe type of intestinal metaplasia was type II in 33 patients and type III in 34 patients. Helicobacter pylori was cured in 67 patients. Follow up showed that changes in type of metaplasia (apparent regression or progression) occurred in both directions and were independent of H pylori status. For example, biopsy sites with "loss" of metaplasia at a follow up visit might have it "reappear" at a subsequent visit. During follow up, no patient developed gastric dysplasia or died from gastric cancer.
Conclusion—HID subtyping did not provide useful information to the clinician or the pathologist. The data are consistent with the notion that the pattern, extent, and severity of atrophy with/without intestinal metaplasia is a far more important predictor of increased cancer risk than intestinal metaplasia subtype.
Key Words: Helicobacter pylori • intestinal metaplasia • high iron diamine • gastric cancer
This article has been cited by other articles:
|
|
 |
|
  S. C. Cunningham, F. Kamangar, M. P. Kim, S. Hammoud, R. Haque, C. A. Iacobuzio-Donahue, A. Maitra, R. Ashfaq, S. Hustinx, R. E. Heitmiller, et al. Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 281 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Ricuarte, O Gutierrez, H Cardona, J G Kim, D Y Graham, and H M T El-Zimaity Atrophic gastritis in young children and adolescents J. Clin. Pathol., November 1, 2005; 58(11): 1189 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W K Leung, S-R Lin, J Y L Ching, K-F To, E K W Ng, F K L Chan, J Y W Lau, and J J Y Sung Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication Gut, September 1, 2004; 53(9): 1244 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Dinis-Ribeiro, C Lopes, A da Costa-Pereira, M Guilherme, J Barbosa, H Lomba-Viana, R Silva, and L Moreira-Dias A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia J. Clin. Pathol., February 1, 2004; 57(2): 177 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P J van Diest and H Holzel Cervical cancer J. Clin. Pathol., April 1, 2002; 55(4): 241 - 242. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
